Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mylan Plans Workforce Reduction After M&A And Price Scandal

Executive Summary

Mylan said it expects to cut less than 10% of its workforce under a restructuring to streamline operations following a series of acquisitions. The news comes amid a spate of negative publicity for the company, including a $465m settlement with the US Department of Justice over EpiPen.

Advertisement

Related Content

Mylan’s Growth Strategy: Diversification, Expansion And R&D Investment
Cold-Eeze Deal Puts Homeopathic Brand At Center Of Mylan Consumer Business
Mylan's Cold-Eeze OTC Acquisition Aims To Leverage Respiratory Expertise
Cold-Eeze Deal Puts Homeopathic Brand At Center Of Mylan Consumer Business
Mylan CEO Takes Center Stage To Address EpiPen Pricing Scandal
Investors Relieved As Mylan Settlement Avoids Investigation
Mylan Finally Nabs Meda In Diversification Play
Mylan seeks women's health power with $800m Famy buy

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097827

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel